Department of Radiation Oncology, University Hospital/Inselspital Bern and University of Bern, 3010 Bern, Switzerland.
Institute for Pathology, University Hospital Basel, 4003 Basel, Switzerland.
Br J Cancer. 2014 Jun 10;110(12):2914-22. doi: 10.1038/bjc.2014.229. Epub 2014 May 22.
Recently, fibroblast growth factor receptor 1 (FGFR1) was discovered in squamous cell carcinomas (SCC) of the lung with FGFR1 amplification described as a promising predictive marker for anti-FGFR inhibitor treatment. Only few data are available regarding prevalence, prognostic significance and clinico-pathological characteristics of FGFR1-amplified and early-stage non-small cell lung carcinomas (NSCLC). We therefore investigated the FGFR1 gene status in a large number of well-characterised early-stage NSCLC.
FGFR1 gene status was evaluated using a commercially available fluorescent in situ hybridisation (FISH) probe on a tissue microarray (TMA). This TMA harbours 329 resected, formalin-fixed and paraffin-embedded, nodal-negative NSCLC with a UICC stage I-II. The FISH results were correlated with clinico-pathological features and overall survival (OS).
The prevalence of an FGFR1 amplification was 12.5% (41/329) and was significantly (P<0.0001) higher in squamous cell carcinoma (SCC) (20.7%) than in adenocarcinoma (2.2%) and large cell carcinoma (13%). Multivariate analysis revealed significantly (P=0.0367) worse 5-year OS in patients with an FGFR1-amplified NSCLC.
FGFR1 amplification is common in early-stage SCC of the lung and is an independent and adverse prognostic marker. Its potential role as a predictive marker for targeted therapies or adjuvant treatment needs further investigation.
最近，在肺鳞癌（SCC）中发现了成纤维细胞生长因子受体 1（FGFR1），FGFR1 扩增被描述为抗 FGFR 抑制剂治疗的有前途的预测标志物。关于 FGFR1 扩增和早期非小细胞肺癌（NSCLC）的患病率、预后意义和临床病理特征，仅有少量数据。因此，我们在大量特征明确的早期 NSCLC 中研究了 FGFR1 基因状态。
使用商业上可获得的荧光原位杂交（FISH）探针在组织微阵列（TMA）上评估 FGFR1 基因状态。该 TMA 包含 329 个切除的、福尔马林固定和石蜡包埋的、无淋巴结转移的 UICC 分期 I-II 期 NSCLC。FISH 结果与临床病理特征和总生存期（OS）相关。
FGFR1 扩增的患病率为 12.5%（41/329），在鳞状细胞癌（SCC）（20.7%）中明显高于腺癌（2.2%）和大细胞癌（13%）（P<0.0001）。多变量分析显示，FGFR1 扩增的 NSCLC 患者 5 年 OS 明显较差（P=0.0367）。
FGFR1 扩增在早期 SCC 中很常见，是独立的不良预后标志物。其作为靶向治疗或辅助治疗的预测标志物的潜在作用需要进一步研究。
